Medical Affairs Resources, Structures, and Trends (UPDATE) - Report SummaryBest Practices
The Update to the wildly popular Medical Affairs Resources, Structures, and Trends research from 2009 is ready! Contains linear data and new segmentation for emerging markets.
Charged with building and maintaining physician relationships, pharmaceutical Medical Affairs organizations typically oversee several important functions -- including publications, KOL programs, grants and medical education (CME) -- that have been impacted in recent years by a call for increased transparency. As such, forward-looking biopharmaceutical executives are beginning to evaluate Medical Affairs operations to ensure that the vital organization is appropriately structured and resourced to operate effectively in the current environment.
This Best Practices, LLC study explores how U.S. and global biopharmaceutical companies are structuring and managing their Medical Affairs organizations today. The study also examines recent trends in budget and staffing resources, key challenges and top success factors for the function.
The report is based on the insights of 68 Medical Affairs executives and managers at 50 leading global companies. The benchmark class in this study consists of a Mature Markets and Emerging Markets Segment. The Mature Market Segment includes 41 participants from pharma and 12 device respondents. The Emerging Markets Segment consists of 15 participants working in India, China, Brazil, and Turkey.
The BIOTECH Equity Strategy Practices Survey provides two types of comprehensive compensation information specifically geared towards life science companies: complete equity strategy information and executive pay and practices information. The results of this survey will be invaluable for those responsible for the company’s equity programs and to those involved in the executive compensation process.
The document discusses the role and responsibilities of Medical Affairs departments within pharmaceutical companies. It describes how Medical Affairs operates medical information functions, provides insights from research to brand teams, cultivates relationships with key opinion leaders, and oversees publication planning and medical writing. Medical Affairs contributes to promotional review and provides market intelligence. The functions of Medical Affairs are organized globally and sometimes by business unit or therapeutic area at the local level. Key areas of specialization within Medical Affairs include medical services, medical research, and medical liaisons.
The best Medical Affairs organizations are evolving from a support-only function to a strategic partner of the business. Explore a common set of Medical Affairs challenges with other leaders from Pharma, Biotech, and Medical Device companies.
Benchmarking Quality: How Medical Device and Diagnostics Companies Manage Cos...Best Practices
Medical device and diagnostics companies spend millions to ensure their products meet quality standards at every stage of the product lifecycle, from R&D to post-market activity. Facing tight budgets and escalating regulations, quality leaders are preparing to shift resources, automate and outsource activities, develop and retain key talent, and build business plans that justify their budgets.
This Best Practices, LLC, report delivers comprehensive survey benchmarks on how medical device companies are defining and allocating Quality spend, identifying factors that impact spending levels, and investing in future mission-critical Quality activities.
Quality leaders can use the evidence-based metrics and insights for Quality spending, staffing, change request levels, outsourcing, software quality, inspections, lab testing, complaint management, trend insights and more.
Msl activities-and-performance-measurement-cutting-edge-information-ph178-bro...Manny Garcia MD
This report provides benchmarks and metrics for medical science liaison (MSL) teams at pharmaceutical and medical device companies. It examines MSL activities in areas like thought leader management, supporting medical/clinical teams, education, and performance measurement. The report is based on surveys of over 30 companies and contains over 160 charts and tables analyzing MSL metrics across different company sizes and regions. It aims to help companies improve coordination of MSL activities and demonstrate their value.
Warranty Management Excellence Measuring Performance through Product Return D...Best Practices
Many companies are seeking ways to serve the underappreciated Employer Market in a complementary approach to the traditional pharma commercial model. Efforts focus on building long-term business relationships and working as a kind of consultative partner who can help employers improve not only health outcomes for employees but also business outcomes in general.
Study Objective – Analyzes how leading companies are approaching interaction with Employer Markets and how they structurally organize their employer groups, and carry out activities in the field. Managed care, managed markets and other sales and marketing heads can use the metrics and narrative insights contained in this study to compare their employer groups to those of other top companies, or to spearhead a new employer market effort within their own organization.
Report Summary--Maintaining a Competitive Edge in Pharmaceutical Public Affairs: Benchmarking the Resources Required to Serve the U.S. Market. Contact me to view the full report.
Medical Affairs Resources, Structures, and Trends (UPDATE) - Report SummaryBest Practices
The Update to the wildly popular Medical Affairs Resources, Structures, and Trends research from 2009 is ready! Contains linear data and new segmentation for emerging markets.
Charged with building and maintaining physician relationships, pharmaceutical Medical Affairs organizations typically oversee several important functions -- including publications, KOL programs, grants and medical education (CME) -- that have been impacted in recent years by a call for increased transparency. As such, forward-looking biopharmaceutical executives are beginning to evaluate Medical Affairs operations to ensure that the vital organization is appropriately structured and resourced to operate effectively in the current environment.
This Best Practices, LLC study explores how U.S. and global biopharmaceutical companies are structuring and managing their Medical Affairs organizations today. The study also examines recent trends in budget and staffing resources, key challenges and top success factors for the function.
The report is based on the insights of 68 Medical Affairs executives and managers at 50 leading global companies. The benchmark class in this study consists of a Mature Markets and Emerging Markets Segment. The Mature Market Segment includes 41 participants from pharma and 12 device respondents. The Emerging Markets Segment consists of 15 participants working in India, China, Brazil, and Turkey.
The BIOTECH Equity Strategy Practices Survey provides two types of comprehensive compensation information specifically geared towards life science companies: complete equity strategy information and executive pay and practices information. The results of this survey will be invaluable for those responsible for the company’s equity programs and to those involved in the executive compensation process.
The document discusses the role and responsibilities of Medical Affairs departments within pharmaceutical companies. It describes how Medical Affairs operates medical information functions, provides insights from research to brand teams, cultivates relationships with key opinion leaders, and oversees publication planning and medical writing. Medical Affairs contributes to promotional review and provides market intelligence. The functions of Medical Affairs are organized globally and sometimes by business unit or therapeutic area at the local level. Key areas of specialization within Medical Affairs include medical services, medical research, and medical liaisons.
The best Medical Affairs organizations are evolving from a support-only function to a strategic partner of the business. Explore a common set of Medical Affairs challenges with other leaders from Pharma, Biotech, and Medical Device companies.
Benchmarking Quality: How Medical Device and Diagnostics Companies Manage Cos...Best Practices
Medical device and diagnostics companies spend millions to ensure their products meet quality standards at every stage of the product lifecycle, from R&D to post-market activity. Facing tight budgets and escalating regulations, quality leaders are preparing to shift resources, automate and outsource activities, develop and retain key talent, and build business plans that justify their budgets.
This Best Practices, LLC, report delivers comprehensive survey benchmarks on how medical device companies are defining and allocating Quality spend, identifying factors that impact spending levels, and investing in future mission-critical Quality activities.
Quality leaders can use the evidence-based metrics and insights for Quality spending, staffing, change request levels, outsourcing, software quality, inspections, lab testing, complaint management, trend insights and more.
Msl activities-and-performance-measurement-cutting-edge-information-ph178-bro...Manny Garcia MD
This report provides benchmarks and metrics for medical science liaison (MSL) teams at pharmaceutical and medical device companies. It examines MSL activities in areas like thought leader management, supporting medical/clinical teams, education, and performance measurement. The report is based on surveys of over 30 companies and contains over 160 charts and tables analyzing MSL metrics across different company sizes and regions. It aims to help companies improve coordination of MSL activities and demonstrate their value.
Warranty Management Excellence Measuring Performance through Product Return D...Best Practices
Many companies are seeking ways to serve the underappreciated Employer Market in a complementary approach to the traditional pharma commercial model. Efforts focus on building long-term business relationships and working as a kind of consultative partner who can help employers improve not only health outcomes for employees but also business outcomes in general.
Study Objective – Analyzes how leading companies are approaching interaction with Employer Markets and how they structurally organize their employer groups, and carry out activities in the field. Managed care, managed markets and other sales and marketing heads can use the metrics and narrative insights contained in this study to compare their employer groups to those of other top companies, or to spearhead a new employer market effort within their own organization.
Report Summary--Maintaining a Competitive Edge in Pharmaceutical Public Affairs: Benchmarking the Resources Required to Serve the U.S. Market. Contact me to view the full report.
Medical Affairs Leadership Summit, Key APAC Insights - August 2016Lynn Okamoto
1) The document summarizes insights from a medical affairs leadership summit in Asia Pacific that discussed defining medical affairs visions and missions, transforming field medical teams, the role of medical affairs in late-stage development and launch readiness.
2) Key topics included adapting medical affairs visions to evolving healthcare landscapes, enhancing field teams' business skills and ability to generate insights, challenges generating real-world evidence in diverse Asia Pacific markets, and ensuring adequate planning and resources for medical affairs involvement in launches.
3) Attendees discussed how medical affairs can demonstrate greater strategic value by engaging more stakeholders, generating regional insights, and involving earlier in product development and launches.
University of Toledo Medical Center Patient Experience Improvement Strategic ...Ioan Duca
The document outlines UTMC's plan to improve service excellence from 2011-2012. It discusses analyzing performance data, aligning leadership to address issues, selecting engaged employees, and developing a patient-centered culture. The goals are to narrow gaps in outcomes vs experience, engage physicians and staff, and prepare for pay-for-performance programs emphasizing quality and satisfaction.
This document summarizes the findings of a SHRM poll on consumer-directed health plans (CDHPs) in the workplace. Key findings include that 42% of organizations offered CDHPs, with large organizations and those with multinational operations being more likely. While 42% of HR professionals felt comfortable with their CDHP knowledge, only 34% at organizations without CDHPs felt this way. Common barriers to offering CDHPs were maintaining the status quo and believing they would not save enough money.
Aligning the Activities and Goals of Field Based Teams for
Strengthened Corporate Sustainability
• Examining the disconnect between field based medical and corporate initiatives
• Acquiring and synthesizing field insights to drive clinical and corporate decision-making
• Demonstrating value of the expensive MSL and Advisor roles to the company
The Medical Science Liaison role is growing and being utilized in a number of various ways by different companies. This presentation discussed how they are being utilized.
The document discusses how rising healthcare costs are negatively impacting business profits and recommends that companies treat healthcare benefits like a major business objective. It promotes the strategy of population health management, which uses data analytics to identify high-risk employees, develop health improvement plans, and partner with employees and providers to implement initiatives that can save companies millions annually through reduced claims costs and an overall healthier workforce. Adopting this approach treats employee health as a business decision that is critical to achieving strategic corporate goals.
From Social Media through to Artificial intelligence...and more. In this presentation I covered the trends that we're currently seeing in Medical Affairs - those trends which are important now, those trends which will impact Medical Affairs in the future, and the skills required to be successful.
To read the LinkedIn article here’s the link: https://www.linkedin.com/pulse/trends-medical-affairs-presented-appa-march-14-2018-glenn-carter/
For further discussion phone us on:
Sydney (02) 8877 8777
Melbourne (03) 9938 7100
Or for additional insights go to one of our specialised websites:
Healthcare Professionals Group
(https://www.hpgconnect.com/)
Health & Aged Care Professionals (https://www.hacpconnect.com/)
Pharmaceutical & Medical Professionals
(https://www.pmpconnect.com/)
Rural & Remote Healthcare Professionals
(https://www.rrhpconnect.com/)
This document summarizes key issues facing hospitals as the healthcare industry consolidates. Large integrated regional health systems will dominate as payment shifts from volume to value. Community hospitals must determine whether to remain independent or affiliate through acquisition or merger. The first step is an objective analysis of strengths, weaknesses, and market position. Scenario planning is also essential to contemplate potential paths. Cultural fit is important for successful consolidation deals. Engaging local stakeholders can help independent hospitals remain viable in their communities.
The document discusses the evolution of medical science liaison (MSL) teams from the 1980s to present day. It describes how MSL teams initially focused on post-marketing activities but now also contribute value to clinical drug development processes like trial design and identification of new indications. The document provides examples of how MSL teams have helped pharmaceutical companies gain regulatory approval faster, lower development costs, and increase drug revenues.
Strategies to Increase Medical Affairs' Role in Health Outcomes Data Generati...Best Practices
With the shift toward evidence-based medicine and value-based pricing, many bio-pharmaceutical companies are transitioning their Health Economics and Outcomes Research (HEOR) function away from the Commercial organization to Medical Affairs. This has some major implications towards the interactions with key stakeholders, the way interactions are documented and the skill sets & activities that may be required. Development of strong health outcomes capabilities within Medical Affairs organizations requires an increase in that function’s involvement with health outcomes groups, development of field-based health outcomes capabilities, customization of health outcomes data by stakeholders and building real world data capabilities to generate and utilize health outcomes information.
Best Practices, LLC undertook this study to identify strategies to increase MA’s role in Health Outcomes data generation and utilization. Specifically, the study highlights the role of Medical Affairs function in HO activities, industry drivers and resource levels for HO groups, challenges of MA’s involvement in HO activities and strategies for effective HO data communication and utilization.
Download Full Report: http://bit.ly/2dGFAbz
This presentation gives an insight into the membership benefits of Best Practices, LLC’s Medical Affairs Consortium. It also highlights some of the key benchmarks and best practices that emerged from Medical Affairs Consortium.
The Medical Affairs Consortium at Best Practices, LLC provides a dedicated platform to Medical Affairs Leaders to discuss top challenges, develop action oriented solutions, share best practices & lessons learned and explore current and future trends with regards to the Medical Affairs function and its interactions with other critical functions.
Topics for the Medical Affairs Consortium are usually determined by member requests. The Medical Affairs Consortium addresses three key areas:
• Building Strong Medical Affairs Capabilities
• Medical Affairs Launch Support Excellence
• Medical Affairs’ Critical Role in Health Economics & Outcomes Research
SHRM Survey Findings: 2013 Employer Perspectives on Disability Benefits--Comp...shrm
This is part two of the five-part series conducted in collaboration with MassMutual. Approximately one quarter (22%) of organizations include variable compensation (e.g., bonuses and commission) in their group long-term disability plan. Among the organizations that do protect variable compensation in their long-term disability plan, 93% indicate the compensation is protected at the same percentage as the base plan selection.
Highlights From 7th Medical Science Liaison/MSL ConferenceExL Pharma
Current trends, issues and challenges facing MSL's in the pharmaceutical industry. Presented at the 7th MSL Best Practices conference, April, 2010. For further information, please visit www.exlpharma.com
SHRM Survey Findings: 2013 Employer Perspectives on Disability Benefits--Exec...shrm
This is the last part of the five-part series conducted in collaboration with MassMutual. Nearly one-third (31%) of organizations offer a special class of benefits to their executives. Among those organizations, 31% provide executives Group Universal Life (GUL) or Group Variable Universal Life (GVUL) as a carve-out benefit from their group term plan.
The Outstanding Organization: Building the Foundation for Everyday ExcellenceTKMG, Inc.
To subscribe: http://www.ksmartin.com/subscribe
To buy the book: http://bit.ly/TOObk
These are slides from a keynote given on 11/5/13 in Stockholm, Sweden at the Nordic Forum for Improvements which was organized by C2 Management.
This keynote focused on the four requirements for excellence in any endeavor: clarity, focus, discipline, and engagement.
For more information on C2 Management visit them at: http://www.c2management.se.
Given the stringent regulatory requirements in the health care industry, it is important for bio-pharmal companies to develop innovative Risk Evaluation and Mitigation Strategies (REMS) plans during the commercialization of certain products to ensure an acceptable risk-to-benefit ratio.
This benchmark study published by Best Practices, LLC examines how companies develop and execute successful Risk Evaluation and Mitigation Strategies (REMS) plans for newly-approved drugs in the U.S. market. This study can help bio-pharma companies in creating successful REMS programs.
Download Full Report: http://bit.ly/2aOt5Id
Physician e-sampling is an established tactic used by pharmaceutical companies to provide drug samples directly to physicians. The study found that while sales representatives remain the primary sampling channel, e-sampling is growing and accounts for about one-third of all sampling currently. Key drivers for implementing e-sampling programs are addressing shrinking sales forces and improving physician access. Most companies see e-sampling as positively contributing to their sales and marketing efforts, though only one in five strongly agree it greatly contributes. Innovation in e-sampling is focusing on supplemental approaches like tele-sampling and email/fax programs.
Physician e-sampling is an established marketing tactic used across many pharmaceutical companies and therapeutic areas to supplement diminished sales representative access to physicians. The key drivers for physician e-sampling programs are addressing issues like shrinking sales forces and restricted physician access. Most companies implement e-sampling programs to support increased sales, provide greater physician access, improve cost-effectiveness, and help build relationships. The number of monthly e-sampling requests varies significantly depending on the therapeutic areas and company sales structures.
Advocacy Excellence: Optimizing Group Structure & Operations Report SummaryBest Practices
Patient advocacy groups have evolved into organizations that play a critical role in educating patients. Correspondently, the advocacy function within pharma has grown in importance as collaborations with patient groups are linked to enhanced disease state and brand education among patient groups.
This Best Practices
®, LLC study identifies key trends in how pharma advocacy group serve internal customers and which activities have the most value. Additionally, the study examines the roles and responsibilities of advocacy. Advocacy group leaders can use this study to better align their relationships with internal and external customers.
This document discusses trends in corporate structure and operations. It provides an executive summary and literature review on commercial structures. The document also includes a case study on Novartis' business unit structure and discusses trends in corporate affairs group structures and services. Finally, it lists the participant companies in the benchmark research on corporate affairs excellence and optimization.
Sales Force Effectiveness- Uncovering How Pharmaceutical Companies Serve the ...Best Practices
The document discusses best practices for pharmaceutical companies' sales forces that target the US hospital market. It provides definitions for key terms related to hospital market segments, decision-makers, and sales force structures. The study aims to understand how to effectively develop a sales force to get products on hospital formularies for different market segments and customer profiles.
Medical Affairs Leadership Summit, Key APAC Insights - August 2016Lynn Okamoto
1) The document summarizes insights from a medical affairs leadership summit in Asia Pacific that discussed defining medical affairs visions and missions, transforming field medical teams, the role of medical affairs in late-stage development and launch readiness.
2) Key topics included adapting medical affairs visions to evolving healthcare landscapes, enhancing field teams' business skills and ability to generate insights, challenges generating real-world evidence in diverse Asia Pacific markets, and ensuring adequate planning and resources for medical affairs involvement in launches.
3) Attendees discussed how medical affairs can demonstrate greater strategic value by engaging more stakeholders, generating regional insights, and involving earlier in product development and launches.
University of Toledo Medical Center Patient Experience Improvement Strategic ...Ioan Duca
The document outlines UTMC's plan to improve service excellence from 2011-2012. It discusses analyzing performance data, aligning leadership to address issues, selecting engaged employees, and developing a patient-centered culture. The goals are to narrow gaps in outcomes vs experience, engage physicians and staff, and prepare for pay-for-performance programs emphasizing quality and satisfaction.
This document summarizes the findings of a SHRM poll on consumer-directed health plans (CDHPs) in the workplace. Key findings include that 42% of organizations offered CDHPs, with large organizations and those with multinational operations being more likely. While 42% of HR professionals felt comfortable with their CDHP knowledge, only 34% at organizations without CDHPs felt this way. Common barriers to offering CDHPs were maintaining the status quo and believing they would not save enough money.
Aligning the Activities and Goals of Field Based Teams for
Strengthened Corporate Sustainability
• Examining the disconnect between field based medical and corporate initiatives
• Acquiring and synthesizing field insights to drive clinical and corporate decision-making
• Demonstrating value of the expensive MSL and Advisor roles to the company
The Medical Science Liaison role is growing and being utilized in a number of various ways by different companies. This presentation discussed how they are being utilized.
The document discusses how rising healthcare costs are negatively impacting business profits and recommends that companies treat healthcare benefits like a major business objective. It promotes the strategy of population health management, which uses data analytics to identify high-risk employees, develop health improvement plans, and partner with employees and providers to implement initiatives that can save companies millions annually through reduced claims costs and an overall healthier workforce. Adopting this approach treats employee health as a business decision that is critical to achieving strategic corporate goals.
From Social Media through to Artificial intelligence...and more. In this presentation I covered the trends that we're currently seeing in Medical Affairs - those trends which are important now, those trends which will impact Medical Affairs in the future, and the skills required to be successful.
To read the LinkedIn article here’s the link: https://www.linkedin.com/pulse/trends-medical-affairs-presented-appa-march-14-2018-glenn-carter/
For further discussion phone us on:
Sydney (02) 8877 8777
Melbourne (03) 9938 7100
Or for additional insights go to one of our specialised websites:
Healthcare Professionals Group
(https://www.hpgconnect.com/)
Health & Aged Care Professionals (https://www.hacpconnect.com/)
Pharmaceutical & Medical Professionals
(https://www.pmpconnect.com/)
Rural & Remote Healthcare Professionals
(https://www.rrhpconnect.com/)
This document summarizes key issues facing hospitals as the healthcare industry consolidates. Large integrated regional health systems will dominate as payment shifts from volume to value. Community hospitals must determine whether to remain independent or affiliate through acquisition or merger. The first step is an objective analysis of strengths, weaknesses, and market position. Scenario planning is also essential to contemplate potential paths. Cultural fit is important for successful consolidation deals. Engaging local stakeholders can help independent hospitals remain viable in their communities.
The document discusses the evolution of medical science liaison (MSL) teams from the 1980s to present day. It describes how MSL teams initially focused on post-marketing activities but now also contribute value to clinical drug development processes like trial design and identification of new indications. The document provides examples of how MSL teams have helped pharmaceutical companies gain regulatory approval faster, lower development costs, and increase drug revenues.
Strategies to Increase Medical Affairs' Role in Health Outcomes Data Generati...Best Practices
With the shift toward evidence-based medicine and value-based pricing, many bio-pharmaceutical companies are transitioning their Health Economics and Outcomes Research (HEOR) function away from the Commercial organization to Medical Affairs. This has some major implications towards the interactions with key stakeholders, the way interactions are documented and the skill sets & activities that may be required. Development of strong health outcomes capabilities within Medical Affairs organizations requires an increase in that function’s involvement with health outcomes groups, development of field-based health outcomes capabilities, customization of health outcomes data by stakeholders and building real world data capabilities to generate and utilize health outcomes information.
Best Practices, LLC undertook this study to identify strategies to increase MA’s role in Health Outcomes data generation and utilization. Specifically, the study highlights the role of Medical Affairs function in HO activities, industry drivers and resource levels for HO groups, challenges of MA’s involvement in HO activities and strategies for effective HO data communication and utilization.
Download Full Report: http://bit.ly/2dGFAbz
This presentation gives an insight into the membership benefits of Best Practices, LLC’s Medical Affairs Consortium. It also highlights some of the key benchmarks and best practices that emerged from Medical Affairs Consortium.
The Medical Affairs Consortium at Best Practices, LLC provides a dedicated platform to Medical Affairs Leaders to discuss top challenges, develop action oriented solutions, share best practices & lessons learned and explore current and future trends with regards to the Medical Affairs function and its interactions with other critical functions.
Topics for the Medical Affairs Consortium are usually determined by member requests. The Medical Affairs Consortium addresses three key areas:
• Building Strong Medical Affairs Capabilities
• Medical Affairs Launch Support Excellence
• Medical Affairs’ Critical Role in Health Economics & Outcomes Research
SHRM Survey Findings: 2013 Employer Perspectives on Disability Benefits--Comp...shrm
This is part two of the five-part series conducted in collaboration with MassMutual. Approximately one quarter (22%) of organizations include variable compensation (e.g., bonuses and commission) in their group long-term disability plan. Among the organizations that do protect variable compensation in their long-term disability plan, 93% indicate the compensation is protected at the same percentage as the base plan selection.
Highlights From 7th Medical Science Liaison/MSL ConferenceExL Pharma
Current trends, issues and challenges facing MSL's in the pharmaceutical industry. Presented at the 7th MSL Best Practices conference, April, 2010. For further information, please visit www.exlpharma.com
SHRM Survey Findings: 2013 Employer Perspectives on Disability Benefits--Exec...shrm
This is the last part of the five-part series conducted in collaboration with MassMutual. Nearly one-third (31%) of organizations offer a special class of benefits to their executives. Among those organizations, 31% provide executives Group Universal Life (GUL) or Group Variable Universal Life (GVUL) as a carve-out benefit from their group term plan.
The Outstanding Organization: Building the Foundation for Everyday ExcellenceTKMG, Inc.
To subscribe: http://www.ksmartin.com/subscribe
To buy the book: http://bit.ly/TOObk
These are slides from a keynote given on 11/5/13 in Stockholm, Sweden at the Nordic Forum for Improvements which was organized by C2 Management.
This keynote focused on the four requirements for excellence in any endeavor: clarity, focus, discipline, and engagement.
For more information on C2 Management visit them at: http://www.c2management.se.
Given the stringent regulatory requirements in the health care industry, it is important for bio-pharmal companies to develop innovative Risk Evaluation and Mitigation Strategies (REMS) plans during the commercialization of certain products to ensure an acceptable risk-to-benefit ratio.
This benchmark study published by Best Practices, LLC examines how companies develop and execute successful Risk Evaluation and Mitigation Strategies (REMS) plans for newly-approved drugs in the U.S. market. This study can help bio-pharma companies in creating successful REMS programs.
Download Full Report: http://bit.ly/2aOt5Id
Physician e-sampling is an established tactic used by pharmaceutical companies to provide drug samples directly to physicians. The study found that while sales representatives remain the primary sampling channel, e-sampling is growing and accounts for about one-third of all sampling currently. Key drivers for implementing e-sampling programs are addressing shrinking sales forces and improving physician access. Most companies see e-sampling as positively contributing to their sales and marketing efforts, though only one in five strongly agree it greatly contributes. Innovation in e-sampling is focusing on supplemental approaches like tele-sampling and email/fax programs.
Physician e-sampling is an established marketing tactic used across many pharmaceutical companies and therapeutic areas to supplement diminished sales representative access to physicians. The key drivers for physician e-sampling programs are addressing issues like shrinking sales forces and restricted physician access. Most companies implement e-sampling programs to support increased sales, provide greater physician access, improve cost-effectiveness, and help build relationships. The number of monthly e-sampling requests varies significantly depending on the therapeutic areas and company sales structures.
Advocacy Excellence: Optimizing Group Structure & Operations Report SummaryBest Practices
Patient advocacy groups have evolved into organizations that play a critical role in educating patients. Correspondently, the advocacy function within pharma has grown in importance as collaborations with patient groups are linked to enhanced disease state and brand education among patient groups.
This Best Practices
®, LLC study identifies key trends in how pharma advocacy group serve internal customers and which activities have the most value. Additionally, the study examines the roles and responsibilities of advocacy. Advocacy group leaders can use this study to better align their relationships with internal and external customers.
This document discusses trends in corporate structure and operations. It provides an executive summary and literature review on commercial structures. The document also includes a case study on Novartis' business unit structure and discusses trends in corporate affairs group structures and services. Finally, it lists the participant companies in the benchmark research on corporate affairs excellence and optimization.
Sales Force Effectiveness- Uncovering How Pharmaceutical Companies Serve the ...Best Practices
The document discusses best practices for pharmaceutical companies' sales forces that target the US hospital market. It provides definitions for key terms related to hospital market segments, decision-makers, and sales force structures. The study aims to understand how to effectively develop a sales force to get products on hospital formularies for different market segments and customer profiles.
Regulatory Affairs Excellence: Staffing and Performance in Medical Device Com...Best Practices
Regulatory affairs group ensure that medical device companies comply with volatile regulatory environment pertaining to developing and marketing medical device products. These specialized groups rely on their own internal effectiveness and efficiencies for enhanced performance under stringent compliance norms. Also, optimal resourcing and staffing helps Regulatory Affairs groups in the medical device industry prioritize roles and responsibilities that will be most beneficial to growth.
Best Practices, LLC conducted this benchmarking study to establish meaningful metrics and insights around the structure, activities, roles and responsibilities of Regulatory Affairs groups at medical device companies. The study also provides recent spend and staffing trends of regulatory affairs in medical device sector, including the use of outsourcing and off-shoring.
Medical device regulatory leaders can use this study to align their staff as per strategies of best in class companies for an increased performance delivery.
Professional and Trade Relations Excellence Report SummaryBest Practices
Professional and Trade relations (PTR) groups play a critically important role in optimizing the reputation of pharma-biotechnology companies among professional, payer and patient groups. However effective functioning of PTR group largely depends upon there structure, funds received and internal awareness about role of PTR groups.
Best Practices ®, LLC undertook this research to help PTR leaders meet these critical challenges and align themselves with corporate goals and objectives. Additionally it also identifies industry trends and pitfalls to avoid while complying with changing needs and optimizing PTR groups. Pharmaceutical executives can use this research document to benchmark their current PTR functions with those of best- in- class companies.
Medical Affairs Resources, Structures & Trends Report SummaryBest Practices
This study was designed to provide metrics and executive insights on the structure and function of early-stage commercialization organizations within pharmaceutical and biotechnology companies.
This is the summary of a webinar I delivered in November 2012 on Health Outcomes Liaisons and their roles in supporting managed care busines and ACO business.
With its influence over key external and internal activities, Corporate Affairs – also known as Public Affairs - is an important function for organizations that must interact with external stakeholders and governmental bodies. Groups that often reside in Corporate Affairs include Policy, Government Affairs, Internal/External Communications and Patient Advocacy. This research project provides an overview of structural approaches to how Corporate Affairs groups are organized and factors influencing structural approaches. The study also includes a number of examples of different organizational models for Corporate Affairs across organizations large and small. Executives in Corporate Affairs can use this research to compare their structure and organizational approach with that of leading organizations.
Medical Affairs Resources, Structures, & Trends Report SummaryBest Practices, LLC
This survey summarizes research on resources, structures, and trends in medical affairs organizations. The survey collected data from 26 medical affairs leaders at 25 pharmaceutical companies. Key findings include that medical affairs groups typically have a centralized structure reporting to executives, focus over a third of their budget on clinical operations, and have experienced few decreases in resources despite some companies citing economic or product reasons. The research was conducted by Best Practices, LLC to benchmark medical affairs organizations.
http://www.modernhealthcare.com/article/20140514/SPONSORED/305149926/webinar-turning-insight-into-action-analytics-effective-denials
Join us to learn how leaders at Middlesex Hospital turned insight into action by leveraging analytics to drive financial performance. This presentation will showcase how Middlesex streamlined its Denials Management process by using analytics to identify trends and opportunities for improvement, as well as for departmental managers to monitor operational aspects of the business.
By attending this webinar, you will learn:
- How post-denial write-off analytics provide immediate feedback for targeting payers, service type, denial type and/or high-dollar areas
- The impact near-real-time data can have on the feedback loops working with clinical departments
- The financial benefit of investing in a dedicated a Denials Management team
Many leading pharmaceutical companies recognize the need to explore different means and mechanisms to supply physicians and their patients with samples of prescription medications. This is especially true since many physicians have restricted access to the sales reps that traditionally helped order and restock samples as part of their detailing visits.
While some companies have made substantial forays into the world of physician e-sampling, usually as a supplement to traditional sampling, others have done less in this area. This is important when you consider that 30 percent of patients in the United States are more likely to fill a prescription after initially receiving a sample from a physician. This study identifies and documents current practices and trends in physician e-sampling and explores the rationale for different tactical approaches to sampling and what constitutes success in physician e-sampling.
This document is a quarterly newsletter from The Sarian Group tracking the Philadelphia life sciences industry. It includes the following:
1. An article on the importance of competitive intelligence for biotech companies.
2. An article on considerations for pre-IPO recruiting and engagement of search firms.
3. A section tracking the performance of local publicly traded life sciences companies through an index and providing the top gainers and decliners year-to-date.
4. An interview with the CEO of Egalet on strategies for driving a company towards an exit through strategic sale or IPO.
This document is a quarterly newsletter from The Sarian Group tracking the Philadelphia life sciences industry. It includes the following:
1. An article on the importance of competitive intelligence for biotech companies.
2. An article on considerations for pre-IPO recruiting and engagement of search firms.
3. A section showing the performance of The Sarian Group Index which tracks publicly traded life sciences companies in the region against benchmarks. It lists top gainers and decliners year-to-date.
4. An interview with the CEO of Egalet on strategies for driving a company towards a strategic sale or IPO.
This document provides a summary of a pharma key account management report from 2011-2012. The report examines the successful implementation of key account management (KAM) in order to increase stakeholder satisfaction, market share, and profitability. It discusses organizational changes needed to transition to a KAM model, challenges in measurement and incentivization, and examples of delivering value to key accounts. The summary provides high-level insights into the challenges and opportunities of implementing KAM strategies.
Similar to US Managed Care Staffing & Resourcing Report Summary (20)
Growing Bio-pharma Digital Marketing Impact by Digitizing Launch, Developing ...Best Practices
It has become quite crucial to identify the drivers of digital marketing performance excellence in the health care industry which will enable companies to gain valuable customer insights, build effective relationships, leverage online media, and maximize revenue.
Best Practices, LLC undertook this benchmarking research to provide critical insights into how savvy bio-pharma digital marketers are enhancing the medical and commercial potential of new products, improving alignment with brand teams, acquiring and training new digital marketers, managing service delivery for key programs and optimizing insource vs. outsource mix.
Download Full Report: http://bit.ly/2gnXrIu
Drive Growth and Profitability Through Strategic Pharmaceutical New Product P...Best Practices
This document summarizes a benchmarking study of new product planning structures and activities at 15 pharmaceutical and biotech companies. Key findings include:
- Global teams transition from planning to marketing earlier than regional teams.
- Global teams begin branding activities like naming in phase II, while regional teams start in phase III.
- Global teams value segmentation and positioning most, while regional teams value market research.
- Global new product planning is more centralized while regional structures are more hybrid.
Best-in-Class Strategies to Develop Effective Medical Information GroupsBest Practices
Medical information groups within bio-pharmaceutical companies play a vital role in the management of publications and product inquiries during the commercialization of drugs.
However, recent regulatory changes in the industry have made it imperative for the Medical Affairs function to align its medical information activities with compliance requirements.
This Best Practices, LLC report establishes benchmarks on the critical requirements to create strong medical information groups. In particular, this report identifies best practices in internal collaboration, alignment of information activities with compliance requirements and the structure, leadership and resource levels required to develop best-in-class medical information groups.
Download Full Report: http://bit.ly/2ewac07
Best Practices in Patient Advocacy Groups Collaboration and Relationship Mana...Best Practices
This document summarizes a study examining best practices for collaborating with patient advocacy groups. It provides an overview of the research methodology, participating companies, key findings and insights. Some of the main findings include: 1) there is no single best structure for patient advocacy groups, with companies taking decentralized, centralized and hybrid approaches; 2) social media and video platforms are increasingly important in patient education; and 3) transparency, aligning objectives, and trust are critical when working with advocacy groups on controversial therapies.
Optimize the Role of Medical Affairs in Health Economics & Outcomes Research ...Best Practices
The Medical Affairs function plays an important role in health outcomes (HO) information exchange between bio-pharmaceutical organizations and key external stakeholders.
Development of robust health outcomes capabilities within Medical Affairs function requires an increase in the function’s involvement with health outcomes groups, development of field-based health outcomes capabilities, customization of health outcomes data as per stakeholders’ needs, and building real world data capabilities to generate and utilize health outcomes information.
This benchmarking research from Best Practices, LLC is designed to assist companies focused on oncology therapies find better ways to develop effective health outcomes groups. It provides current data and best practices from Medical Affairs leaders with an oncology focus at leading bio-pharmaceutical companies.
Download Full Report: http://bit.ly/2e3sl9Q
Benchmarking Bio-Pharmaceutical Medical Education Programs: Structures, Resou...Best Practices
This document provides a summary of a benchmarking study conducted by Best Practices, LLC on medical education structures, resources, and activities at major biopharmaceutical companies. Some key findings include:
- Most companies (over 75%) take a centralized approach to organizing their medical education functions. Nearly half centralize in the US.
- Companies heavily rely on outsourcing, delegating 86% of program development and all program deployment to vendors.
- Respondents were primarily directors or senior directors of medical education functions, with some managers. Insights were drawn from leaders across various roles and geographies.
Emerging Medical Education Trends in the Medical Device Industry: Benchmarks ...Best Practices
Medical education programs play an important role in informing health care professionals about the safe and effective use of medical devices.
To probe emerging medical education trends in the device sector, Best Practices, LLC undertook benchmarking research. In particular, this study provides benchmarks on the proper size, structure, funding channels, staffing and investment for medical education groups.
Download Full Report: http://bit.ly/2bY2NZ8
Delays in the launch and execution of critical market research projects can slow down the decision-making process, resulting in missed opportunities and increased costs. Therefore, it is absolutely critical for bio-pharmaceutical companies to develop a tactical approach to expedite the market research approval process for quicker and more meaningful insights.
According to recent research by Best Practices, LLC, nearly three-quarters of the benchmarked study participants use review cycle time as a metric for determining if the market research approval process is functioning at an acceptable level. One tip that participants gave on how to control processes and to ensure high performance is to create checklists. Begin with checklists in pinch points that are most problematic, and then extend to entire process and operations. This report will help leaders to gain critical insights they need to compete successfully in a fast-changing market.
Download Full Report: http://bit.ly/2bfAhOc
Benchmarking Professional Medical Education Excellence StructuresBest Practices
This document summarizes a benchmarking study conducted by Best Practices, LLC on medical education structures, resources, and activities at large biopharmaceutical companies. Key findings include:
- Most companies take a centralized approach to medical education, located in their US market or headquarters country.
- Companies rely heavily on outsourcing, using vendors for 53% of program development and 58% of program delivery on average.
- Staffing is concentrated in North America, with an average of 5 FTEs and $3.23 million budget per FTE. Companies support an average of 170 CME and 98 non-CME programs annually.
Budget Allocation for a Successful Bio-Pharma Product LaunchBest Practices
Bio-Pharma companies can no longer afford to rely solely on past experiences when budgeting for a new product launch in today's fast-changing, highly competitive market. This comprehensive benchmark study by Best Practices, LLC investigates current costs as well as budget and staffing allocations required for a successful drug launch.
This study can help bio-pharma leaders to develop competitive launch and pre-launch activity budgets to ensure successful U.S. market entry for new products.
Download Full Report: http://bit.ly/2aMYron
Driving Performance Excellence in the Regulatory Affairs Function at Medical ...Best Practices
This document summarizes research from a benchmarking study of regulatory affairs practices at 32 leading medical device companies. Key findings include:
- Regulatory affairs structures are most commonly centralized, though some utilize decentralized or hybrid models. Larger companies tend towards more decentralized structures.
- Portfolio complexity, defined as the ratio of class III products, influences but does not solely determine staffing needs.
- On average, companies file over a dozen submissions annually with European regulators and over 60 submissions with Japanese regulators.
- Regulatory staff spend significant time (over 20% for most companies) managing change notices and documentation.
Disease Awareness Program Excellence: Structure, Timing, Activities & Investm...Best Practices
Bio-pharmaceutical companies use disease state awareness campaigns to disseminate unbranded information to external stakeholders such as physicians, patients and payers.
Best Practices, LLC undertook research to deliver benchmarks around the structure, timing, investment and activities for disease awareness programs.
Download Full Report: http://bit.ly/2a7CnUS
Library Services Benchmarks - Using Corporate Library Services in PharmaBest Practices
Libraries are custodians of invaluable information. The study - Library Services Benchmarks 2016: Corporate Library Services in the Pharmaceutical Industry published by Best Practices, LLC examines the trends and staffing benchmarks such as library staff per potential and actual users across companies providing access to library services across the bio-pharmaceutical space.
This study looks into staff with formal education level and the number of staff inside and outside the library who provide library services. This study can be used by bio-pharmaceutical companies to improve upon existing library services and staffing.
Download Full Report: http://bit.ly/29QZcbM
Effective Launch Training Practices for District Sales Managers: Optimize Per...Best Practices
Rising competition and access restrictions in the bio-pharmaceutical industry have made it critical for companies to prepare and measure the performance of their District Sales Managers (DMs) who oversee launch-related activities in the field.
Best Practices, LLC engaged 20 sales leaders from bio-pharmaceutical companies to establish benchmarks around the training and accountability of District Sales Managers at launch. Insights from this study will serve as a reference point for companies to evaluate their launch training programs for the sales force against industry benchmarks.
Download Full Report: http://bit.ly/29Gq68L
Best Practices in Creating Global Brand for New Products and Ensuring Alignme...Best Practices
In order to develop an effective global branding program for new bio-pharmaceutical products, it is important to ensure brand consistency across all functions and geographies.
Best Practices, LLC undertook research to gather benchmarks on key aspects of the global branding process, including activities, timing, positioning, key message development, regional alignment, agency utilization & cost and the tradename process.
Download Full Report: http://bit.ly/2a1XqUV
Benchmarking Advisory Board Management at Mid-Sized Pharmaceutical & Medical ...Best Practices
The document provides a summary of research conducted on benchmarking advisory board management practices at mid-sized pharmaceutical and medical device organizations. Key findings from surveying 35 executives at 29 companies include that mid-sized companies have more advisory board participants on average compared to other companies, prefer national participants for clinical advisory boards, and face challenges in selecting appropriate advisory board members and managing advisory boards. The research was conducted to identify best practices for advisory board structure, selection of participants, operations, costs, and challenges.
Benchmarking Advisory Board Management At Large Pharmaceutical And Medical De...Best Practices
Pharmaceutical advisory boards provide strategic inputs and guidance to organizations on various business aspects. However, successful advisory board management requires optimum investment in resources and operations. To maximize the return on investment it is important for pharmaceutical and medical device professionals to ensure that the quality of meetings and dialogue with advisory boards is excellent.
This research from Best Practices, LLC is designed for pharmaceutical and biotech executives seeking ways to best utilize the knowledge of advisory boards. Research findings provide benchmarks on the appropriate structure for various types of advisory boards, selection of advisory board participants, advisory board operational and resource benchmarks.
Developing High-Impact Communication Forms to Brief Senior Leaders: Optimizin...Best Practices
This document provides a summary of research on developing high-impact communication forms to brief senior leaders on competitive assessments and clinical development summaries. It describes the research methodology, which included surveys and interviews with leaders from 27 bio-pharma companies. Key findings include that executive briefs should be concise (5 pages or less), include general market insights as well as competitor insights, and be created for both new and existing products. Important elements to include are the condition treated, compound name, revenue projections, and probability of success. The document provides templates and recommendations for crafting impactful competitive landscape assessments and clinical development summaries.
Optimizing the Managed Markets Function: Roles, Structures, Resources and Act...Best Practices
This document summarizes the results of a benchmarking analysis that assessed the operational performance of managed markets functions at small and mid-sized pharmaceutical companies. The analysis found that on average these companies dedicate 55% of staff time to account management. It also found that companies feel they could operate with leaner structures, as the perceived ideal ratio of account managers to area directors is lower than current ratios. Additionally, the analysis showed that while account manager compensation is tied 50-50 to MBO and sales plan attainment, area directors compensation weighting shifts more to MBO at 60-40.
Infographic: Mastering Digital Marketing StructureBest Practices
The document discusses trends in digital marketing structure and budgets in the healthcare industry. It recommends reducing costs by outsourcing routine digital marketing functions like SEO. Most healthcare companies plan to increase their digital marketing budgets by over 10% in the next two years, though they currently lag in tracking digital marketing analytics compared to other industries. While 55% of US companies use a hybrid digital marketing structure, the overall trend is toward more centralized structures, as seen in 60% of all companies and 88% of innovative companies centralizing over the last two years.